Results 161 to 170 of about 4,744 (194)

Plasma 5-Fluorouracil Exposure, Clinical Outcomes, and Therapeutic Drug Monitoring in Advanced Colorectal Cancer. [PDF]

Cancers (Basel)
Sakuyama N, Nagayasu K, Abe Y, Ochiai T, Shibasaki F.   +4 more
europepmc   +1 more source

Severe fluoropyrimidine toxicity in a patient with rectal adenocarcinoma with <i>DPYD</i> c.2846A>T heterozygous mutation: A case report. [PDF]

Oncol Lett
Tunc S, Karhan O.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

TYMS and DPYD polymorphisms in a Turkish population

European Journal of Clinical Pharmacology, 2005
The thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) enzymes affect the outcome of 5-fluorouracil (5-FU)-based chemotherapy. Genetic polymorphisms of the thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) genes that may affect chemotherapy are described.
H S, Süzen, N, Yüce, G, Güvenç, Y, Duydu, T, Erke   +4 more
openaire   +2 more sources

Fluoropyrimidine Toxicity: the Hidden Secrets of DPYD

Current Drug Metabolism
Background:: Fluoropyrimidine-induced toxicity is a main limitation of therapy. Currently, polymorphisms in the DPYD gene, which encodes the 5-FU activation enzyme dihydropyrimidine dehydrogenase (DPD), are used to adjust the dosage and prevent toxicity.
Vangelis G. Manolopoulos, Georgia Ragia
openaire   +2 more sources

Suppression of DPYD expression in RKO Cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression

Biochemistry and Cell Biology, 2007
Dihydropyrimidine dehydrogenase (DPD) is one of the factors that determine the efficacy and toxicity of 5-fluorouracil. Variations in DPD activity may result from alterations at the transcriptional level of the DPYD gene. Heterogeneity in DPYD expression has been reported, but the molecular mechanisms responsible for this remain unclear.
Zhang, X., Soong, R., Wang, K., Li, L., Davie, J.R., Guarcello, V., Diasio, R.B.   +6 more
openaire   +2 more sources

Determination of DPYD Enzyme Activity in Korean Population

Therapeutic Drug Monitoring, 2015
Dihydropyrimidine dehydrogenase (DPYD) is an enzyme that regulates the rate-limiting step in pyrimidine metabolism, especially catabolism of fluorouracil. This study was performed to analyze the association between DPYD genetic variants and DPYD enzyme activity in the Korean population.We screened the genetic variants and analyzed the enzyme activity ...
Joong-Gon, Shin, Tae Sun, Kang, Hyun Sub, Cheong, Hee Jung, Shin, Hyun Joo, Park, Han Sung, Na, Hyoung Doo, Shin, Myeon Woo, Chung   +7 more
openaire   +2 more sources

Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers

Anti-Cancer Drugs, 2019
Certain polymorphisms of the DPYD gene encoding for the dihydropyrimidine dehydrogenase (DPD) enzyme are associated with fluoropyrimidine-induced toxicity. Dose reductions of the fluoropyrimidine prodrug capecitabine are recommended for patients carrying these DPYD variants to prevent toxicities.
Jan P, Kleinjan, Ithamar, Brinkman, Robbert, Bakema, Jelmer J, van Zanden, Johan M, van Rooijen   +4 more
openaire   +2 more sources

Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants.

Journal of Clinical Oncology, 2011
10524 Background: Fluoropyrimidines are associated with gastrointestinal and hematologic adverse reactions which may be severe and, in sporadic cases, lethal.
DEL RE, MARZIA, LOUPAKIS F, MICHELUCCI A, DI PAOLO, ANTONELLO, FALCONE, ALFREDO, SIMI P, BOCCI, GUIDO, CANTORE M, BORDONARO R, DI LEO A, BARBARA C, CAPPUZZO F, DE BRAUD F. G, DANESI, ROMANO   +13 more
openaire   +3 more sources

Cloning and Initial Characterization of the Human DPYD Gene Promoter

Biochemical and Biophysical Research Communications, 2000
Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in the degradation of pyrimidine bases and pyrimidine-based antimetabolites. Reduced DPD activity is associated with toxicity to 5-fluorouracil (5FU) therapy in cancer patients and with neurological abnormalities in paediatric patients.
Collie-Duguid ES, Johnston SJ, Powrie RH, Milano G, Etienne MC, Rochat B, Watson GC, McLeod HL   +7 more
openaire   +3 more sources

The role of Sp1 and Sp3 in the constitutive DPYD gene expression

Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 2006
Dihydropyrimidine dehydrogenase (DPD), the initial and rate-limiting enzyme in the 5-fluorouracil (5-FU) catabolic pathway, has been implicated as one of the factors determining the efficacy and toxicity of the anticancer agent 5-FU. Studies have attributed variation in DPD activity partially to alterations at the transcriptional level of DPYD gene. We
Xue, Zhang, Lin, Li, Jeanne, Fourie, James R, Davie, Vincenzo, Guarcello, Robert B, Diasio   +5 more
openaire   +2 more sources